ID: MRFR/HC/6835-CR | 133 Pages | Published By Kinjoll Dey on September 2019
The Glioblastoma Market is expected to register a CAGR of 7.60% to reach USD 2416.33 million by 2030.
The increasing incidence rate of glioblastoma is expected to fuel the growth of the glioblastoma market. According to the statistics published in 2017 by the National Centre for Biotechnology Information (NCBI), glioblastoma has an incidence rate of 3.19 per 100,000 persons in the US. The growing prevalence indirectly increases the healthcare expenditure of the people as well as the government. This motivates the players operating in the market to come up with alternatives for the treatment of glioblastoma. Thus, this is likely to fuel the growth of the global glioblastoma market during the forecast period.
Glioblastoma Global Market Share, by End User, 2018 (%)
Source: MRFR Analysis
The global glioblastoma market has been segmented by type, treatment, and end user. The market, based on type, has been bifurcated into primary glioblastoma and secondary glioblastoma. Based on treatment, the glioblastoma market has been segregated into surgical procedure, radiation therapy, chemotherapy, and others. The global glioblastoma market, based on end user, has been divided into hospitals, specialty clinics and centers, and others. The specialty clinics and centers held a share of 36.8% in 2018.
Western Europe Glioblastoma Market Share, 2018 (%)
Source: MRFR Analysis
The glioblastoma global market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to dominate the global glioblastoma industry. The growth in this region can be attributed to the increased cases of glioblastoma and brain tumors. Moreover, the approval of drugs helps in maximizing the growth of the market in this region.
Europe held a substantial share in the global glioblastoma market. This can be attributed to a large number of clinical trials in the region. For instance, Merck KGaA along with Vaximm GmbH is involved in Phase I and II trials to evaluate the efficacy and safety of VXM01 in combination with Avelumab in patients with resectable and non-resectable progressive glioblastoma following tumor resection and radio-chemotherapy containing temozolomide.
Asia-Pacific is estimated to be the fastest-growing region in the global market. The rise in the improved healthcare infrastructure promises a high level of research on the treatment of glioblastoma in the region.
The glioblastoma market in the Middle East & Africa is expected to witness a modest market growth rate from 2019 to 2025. The Middle East would lead the market growth in this region. Rising awareness regarding health and availability of new treatment methods are expected to drive the market growth during the assessment period.
The prominent players in the global glioblastoma market are F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (US), Merck & Co., Inc. (US), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel).
Some of the key strategies followed by players operating in the global glioblastoma market were innovation, product development, and acquisition & mergers.
Glioblastoma Global Market, by Type
Glioblastoma Global Market, by Treatment
Glioblastoma Global Market, by End User
Glioblastoma Global Market, by Region
Available Additional Customizations
|Market Size||2030: 2416.33 Mn|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||By Type, Treatment , End User and Region|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (US), Merck & Co., Inc. (US), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel)|
|Key Market Opportunities||
|Key Market Drivers||Increases the healthcare expenditure|
glioblastoma market is expected to reach a valuation of USD 2416.33 bmllion by 2030.
The global market is expected to exhibit a strong 7.60% CAGR over the forecast period from 2020 to 2030.
The growing prevalence of glioblastoma is the major driver for the global market.
The Americas are likely to dominate the global glioblastoma market.
Leading players in the market include F. Hoffman-La Roche, Merck, and Amgen, among others.